Quinuclidine derivatives and medicinal compositions...

Details Quinuclidine derivatives and medicinal compositions... Quinuclidine derivatives and medicinal compositions...

2006-07-18

2006-07-18

Aulakh, Charanjit S. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S137000, C546S133000

Reexamination Certificate

active

07078412

ABSTRACT:
The invention provides 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane in salt form, pharmaceutical compositions comprising it, and methods of using it for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds.

REFERENCES:
patent: 4224332 (1980-09-01), Gueremy et al.
patent: 4644033 (1987-02-01), Gnanou et al.
patent: 4675326 (1987-06-01), Amitai et al.
patent: 4843074 (1989-06-01), Rzeszotarski et al.
patent: 5201308 (1993-04-01), Newhouse et al.
patent: 5435301 (1995-07-01), Harold et al.
patent: 5654314 (1997-08-01), Banholzer et al.
patent: 6455524 (2002-09-01), Bozung et al.
patent: 6475467 (2002-11-01), Keller et al.
patent: 6537524 (2003-03-01), Hassan et al.
patent: 6750226 (2004-06-01), Forner et al.
patent: 2002/0193392 (2002-12-01), Schmelzer et al.
patent: 2005/0025718 (2005-02-01), Meade et al.
patent: 2005/0026886 (2005-02-01), Meade et al.
patent: 2005/0026887 (2005-02-01), Meade et al.
patent: 2005/0026948 (2005-02-01), Meade et al.
patent: 0 418 716 (1991-03-01), None
patent: 0 424 021 (1991-04-01), None
patent: 0747355 (1996-12-01), None
patent: 0801067 (1997-10-01), None
patent: 1087750 (1999-08-01), None
patent: 2012964 (1970-03-01), None
patent: 1219606 (1971-01-01), None
patent: 178679 (1982-06-01), None
patent: WO 91/04252 (1991-04-01), None
patent: WO 92/04345 (1992-03-01), None
patent: WO 9632150 (1996-10-01), None
patent: WO 00/47200 (2000-08-01), None
patent: WO 0104118 (2001-01-01), None
patent: WO 01/50080 (2001-07-01), None
patent: WO 01/50080 (2001-07-01), None
patent: WO 0178736 (2001-10-01), None
patent: WO 0178739 (2001-10-01), None
patent: WO 0178741 (2001-10-01), None
patent: WO 0178743 (2001-10-01), None
patent: WO 0236106 (2002-05-01), None
patent: WO 0238154 (2002-05-01), None
patent: WO 0247667 (2002-06-01), None
patent: WO 02/060532 (2002-08-01), None
patent: WO 02/060533 (2002-08-01), None
patent: WO 03000241 (2003-01-01), None
patent: WO 03097613 (2003-11-01), None
patent: WO 04043966 (2004-05-01), None
patent: WO 04058729 (2004-07-01), None
patent: WO 05049581 (2005-06-01), None
U.S. Appl. No. 11/141,428, filed May 31, 2005, Jordi Gras et al.
U.S. Appl. No. 11/141,427, filed May 31, 2005, Jordi Gras et al.
U.S. Appl. No. 11/141,169, filed May 31, 2005, Jordi Gras et al.
U.S. Appl. No. 11/116,777, filed Apr. 28, 2005, Fernandez Forner et al.
Hancox, RJ et al., “Randomised trial on an inhaled β2 agonist, inhaled corticosteroid and their combination in the treatment of asthma,”Thorax, 54:482-487 (1999).
Nishimura et. al., “Additive effect of oxitropium bromide in combination with inhaled corticosteroids in the treatment of elderly patients with chronic asthma,”Allerology International48:85-88 (1999).
Pearson et. al.,Thorax52(Suppl 5): S1-S28 (1997).
Rees, P.J., “Bronchodilators in the therapy of chronic obstructive pulmonary disease,”Eur Respir Mon, 7:135-149 (1998).
Serafin, W. Chapter 28, Drugs Used in the Treatment of Asthma, Goodman & Gilman's the Pharmacological Basis of Therapeutics (Joel G. Hardman et al. eds, 9th ed., 1996) pp. 659-682.
Martindale the Complete Drug Reference (Kathleen Parfitt ed., 32nd ed., 1999) pp. 745-747.
Rang, H.P. et al., Pharmacology (Churchill Livingston Inc., 1995) pp. 358-361.
Spirva® HandiHaler® Prescribing Information, Boehringer Ingelheim International GmbH, 59873/US/2, Sep. 2004.
Combivent® Inhalation Aerosol Prescribing Information, Boehringer Ingelheim International GmbH, 10000291/03, revised Sep. 2001.
Atrovent® Inhalation Aerosol Prescribing Information, Boehringer Ingelheim International GmbH, 10001403/US/1, 10001403/01, revised Mar. 27, 2002.
6001 Chemical Abstracts, Columbus, Ohio, US. vol. 104(19). XP-002128290, p. 659. (1 page total).
Burtner, R. and Cusic, J. W. (1943). “Antispasmodics, II. Basic Esters of Some Polynuclear Carboxylic Acids,”J. Am. Chem. Soc.65:1582-1585.
Cohen, V. I. et al. (1992). “Synthesis and Receptor Affinities of New 3-Quinuclidinyl α-Heteroryl-α-aryl-α-Hydroxyacetates,”J. Pharm. Sciences81:326-329.
Davis, M. A. et al. (1963). “New Psychotropic Agents, VI. Basic Esters of 5-Hydroxydibenzo[a,d]cycloheptadiene-5-carboxylic Acid,”J. Med. Chem6:513-516.
Davis, M. A. et al (1964). “Anticonvulsants. I. Dibenzo[a,d]cycloheptadiene-5-carboxamide and Related Compounds,”J. Med. Chem.7:88-94.
Grob, C. A. and Brenneisen, P. (1958). “Die Synthese von 4-Brom- und 4-Hydroxy-Chinuclidin,”Helv. Chim.Acta 41:1184-1191.
Heacock, R.A. et al. (1958). “Materials and Methods,”The Annals of Applied Biology, Marsh, R. W. and Thomas, I, eds, Cambridge at the University Press, vol. 46, pp. 356-365.
Konzett, H. and Rössler, R. (1940). “Versuchsanordnung zu Untersuchungnen an der Bronchialmuskulatur,”Arch. Exp. Path. Pharmacol.195:71-74.
Kumazawa, T. et al. (1994). “Inhibitors of Acyl-CoA:Cholesterol Acyltransferase. 1. Synthesis and Hypocholesterolemic Activity of Dibenz[b,e]oxepin-11carboxanilides,”J. Med. Chem. 37(6): 804-810.
Larsson, L. et al. (1974). “The Hydrogen Bond Condition in Some Anticholinergic Esters of Glycolic Acids. I,”Acta Pharm. Suec.11(3):304-308.
May, E. L and Mossettig, E. (1948). “Studies in the Anthracene Series. V. A Novel Rearrangement in the Reaction of Halomethyl Ketones with Secondary Amines,”J. Am. Chem. Soc.70: 1077-1079.
Meyers, A. I. et al. (1980). “Resolution of α-Substituted Mandelic Acids via Chiral Oxazolines Using Pressurized Chromatography,”J. Org. Chem.45(14): 2912-2914.
Nyberg, K. et al. (1970). “Investigations of Dithienylglycolic Esters,”Acta Chem. Scand.24:1590-1596.
Rigaudy, J. et al. (1959). “Cétones Derivées du Dibenzo [a,d] cycloheptadiène. La Dibenzo-2-,3-6,7 Cycloheptadiènedione-4,5,”Bull. Soc. Chim. France.638-643.
Ringdahl, R. et al. (1979). “Facile Preparation of the Enantiomers of 3-Acetoxyquinuclidinol,”Acta Pharm Suec.16:281-283.
Sestanj, K. (1971). “A Facile Formation of Dibenzo[a,b]cycloheptenylium Ion by Decarbonylation. Color Reactions of the Cyheptaminde Metabolites,”Can. J. Chem.49:664-665.
Ueda, I. (1975). “The Rearrangement of 10-Bromo-10, 11-Dihydrodibenzo[b,f]thiepin-11-one and Related Compounds in an Alkaline Solution,”Bulletin of the Chemical Society of Japan48(8):2306-2309.
Waelbroek, M. et al. (1990). “Binding of Selective Antagonists to Four Muscarinic Receptors (M1 to M4) in Rat Forebrain,”0Mol. Pharmacol.38:267-273.
Gao, S-H., et al.Stereochemistry of the heterocyclic alcohols containing piperidine unit, Gaodeng Xuexiao Huaxue Xuebao, 1999, pp. 232-236, vol. 20.
Naronha-Blob, L., et al.Stereoselective antimuscarinic effects of 3-quinuclidinyl atrolactate and 3-quinuclidinyl xanthene-9-caboxylate, 1992, pp. 97-103, vol. 211.

Affiliated with

Also associated with

Rating

Quinuclidine derivatives and medicinal compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinuclidine derivatives and medicinal compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinuclidine derivatives and medicinal compositions... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3613099